Navigation Links
New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Date:5/5/2008

100% of Insulin Doses Administered Were Delivered Within Pre-Determined

Guidelines and Standard Dosing Limitations

BRIDGEWATER, N.J., May 5 /PRNewswire-FirstCall/ -- A new study examining the dose accuracy of the SoloSTAR(R) disposable insulin pen, prefilled with Lantus(R) (insulin glargine [rDNA origin] injection) or Apidra(R) (insulin glulisine [rDNA origin] injection), found the pens accurately delivered all insulin doses within standard limits defined by the International Organization for Standardization (ISO). Lantus(R) SoloSTAR(R) was approved by the U.S. Food and Drug Administration (FDA) on April 25, 2007. Apidra(R) for use in the SoloSTAR(R) prefilled disposable pen is currently under review at the FDA. The study, presented on May 2, 2008 at the 43rd Congress of the German Society for Diabetes (DDG) in Munich, Germany, examined the accuracy of both pens at multiple target dosages to determine the proportion of doses that fell within ISO ranges.

"For people with diabetes who use an insulin pen to deliver their insulin, dose accuracy is essential for their treatment," stated Norbert Hermanns, Ph.D., director of the Research Institute of the Diabetes Academy Mergentheim, Bad Mergentheim, Germany, and lead investigator in the study. "Based on the findings of this study, we concluded that the SoloSTAR(R) pen is an accurate insulin delivery option for people with diabetes."

The study participants, a random sample of 60 hospital inpatients with type 1 and type 2 diabetes, were trained on correct use of the SoloSTAR(R) pen. Participants were then asked to inject three target doses with Lantus(R) into an insulin-sponge, in doses of 10 (low), 40 (medium) and 80 (high) units, and three doses of Apidra(R) in doses of 5 (low), 15 (medium) and 30 (high) units. The quantity of insulin delivered was calculated by the weight of the insulin pens before and after injection. The order of the dosages was randomized. All doses (100%) were within the limits prescribed by the ISO standard (mean doses were only 0.9% to 1.3% below targets for Lantus(R), and 0.4% to 1.1% below targets for Apidra(R)), and the data set was within the ISO-defined 97.5% confidence intervals at each dose.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that more than 20 million Americans have diabetes, including an estimated 6.2 million who remain undiagnosed. At the same time, approximately half of those diagnosed are not achieving the general blood sugar control standard of A1C <7 percent recommended by the American Diabetes Association (ADA). The A1C test measures average blood glucose levels over a two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

U.S. Contacts:

Carrie Melia

Carrie.Melia@sanofi-aventis.com

908-981-6486

US.GLA.08.05.001


'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
4. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
5. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
6. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
9. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  Global biotherapeutics leader ... completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ... nd T reatment with H izentra ® ... demonstrate the efficacy, safety and tolerability of two different ... (Immune Globulin Subcutaneous [Human]), compared with placebo, in ...
(Date:3/1/2017)... -- The Welch Foundation, one of the nation,s largest sources ... Drs. Neal M. Alto and Delia ... Norman Hackerman Award in Chemical Research. Both ... significant scientific discoveries at early stages of their careers. ... of the Hackerman Award that two recipients have been ...
(Date:3/1/2017)... Mar 01, 2017 Research and Markets has ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... drug pricing data and benchmarks in the global Acute Myeloid Leukemia ... of your competitor drugs and find out how the marketed products ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... ... Grund® America is proud to announce the new collection of ... International Housewares Show in Chicago (Grund Booth N6466). , “We are very excited about ... and GOTS Organic Cotton material. By adding the GOTS (Global Organic Cotton Standard) ...
(Date:3/1/2017)... ... ... Expert on international living and leading a healthy lifestyle, Alina Reyzelman, announced ... Go app is the ultimate strategic compass that helps users to achieve goals in ... to work smarter, not harder, that's why Time & Go app provides tools and ...
(Date:3/1/2017)... ... March 01, 2017 , ... NYC based Integrated practice Living Well Medical, ... announce the addition of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. Heitman ... University with a Bachelor of Science degree in biology. He then obtained his medical ...
(Date:3/1/2017)... PA (PRWEB) , ... March 01, 2017 , ... ... Penn., has announced special pricing in the month of March for treatments aimed ... Skin ” special features use on Thermage skin tightening, with 30 percent off ...
(Date:3/1/2017)... , ... March 01, 2017 , ... “McFarnia”: a suspenseful ... uncover the truth about his life and mysterious disappearance. “McFarnia” is the creation of ... living in North Carolina. He currently serves as a Chaplain with Transport for Christ ...
Breaking Medicine News(10 mins):